A retrospective cohort study focused on the relationship between antidepressant use in minors and risk for type 2 diabetes—a pattern already detected among adults. The investigation focused on Medicaid claims data for 119,608 patients aged 5–20 years who began antidepressant therapy during the time period covering January 1, 2005–December 31, 2009. Colleagues from the University of Maryland, Baltimore and Johns Hopkins Medical Institutions employed discrete-time failure models to assess incident type 2 diabetes, after adjusting for disease risk score based on dozens of covariates. At a mean 22.8 months after treatment initiation, they found that use of selective serotonin reuptake inhibitors or serotonin-nerephinephrine reuptake inhibitors correlated with elevated likelihood of developing type 2 diabetes. The risk, they additionally discovered, increased the longer the patient took the antidepressants, the higher the average daily dose after 150 days of treatment, and the greater the cumulative dose of drugs.